Zum Hauptinhalt springen

Press Releases and Ad-hoc Announcements

25. April 2024
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
PDF
05. April 2024
PR: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
PDF
27. März 2024
PR: Heidelberg Pharma granted orphan drug designation by FDA for its proprietary ATAC candidate HDP-101
PDF
25. März 2024
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023
PDF
19. März 2024
PR: Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
PDF
18. März 2024
PR: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
PDF
06. März 2024
PR: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
PDF
04. März 2024
PR: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
PDF
04. März 2024
AH: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million
PDF
29. November 2023
PR: Heidelberg Pharma Announces Changes to the Executive Management Board
PDF